Business · 29/03/2005Updated: 10/17/2026 · 1 min read
FDA Refers KEMSTRO (Baclofen) and DROXIA (Hydroxyurea) for Pediatric Studies
Summary
The FDA has referred KEMSTRO (baclofen) and DROXIA (hydroxyurea) to the Foundation for the National Institutes of Health for pediatric studies, as mandated by the Best Pharmaceuticals for Children Act (BCPA), following referrals on September 1, 2004, and October 20, 2004, respectively.